Lebrikizumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients not adequately controlled or non-eligible for cyclosporine: a placebo-controlled, randomized phase 3 clinical study (ADvantage)

被引：0

作者：

Warren, Richard B. ^{[1
]}

de Bruin-Weller, Marjolein ^{[2
]}

Tsianakas, Athanasios ^{[3
]}

Khemis, Abdallah ^{[4
]}

Szepietowski, Jacek C. ^{[5
]}

Hong, H. Chih-Ho ^{[6
]}

Armengol, Clara ^{[7
]}

Falques, Meritxell ^{[7
]}

Agell, Helena ^{[7
]}

Massana, Eric ^{[7
]}

Gil, Esther Garcia ^{[7
]}

Weidinger, Stephan ^{[8
]}

机构：

[1] Univ Manchester, Northern Care Alliance NHS Fdn Trust, Manchester NIHR Biomed Res Ctr, Manchester, England

[2] Univ Med Ctr Utrecht, Utrecht, Netherlands

[3] Fachklin Bad Bentheim, Bad Bentheim, Germany

[4] Polyclin St George Grp Kantys, Dermatol, Nice, France

[5] Med Univ, Wroclaw, Poland

[6] Univ British Columbia, Vancouver, BC, Canada

[7] Almirall SA, Barcelona, Spain

[8] Univ Hosp Schleswig Holstein, Campus Kiel, Kiel, Germany

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 191卷

关键词：

lebrikizumab; topical corticosteroids; investigator global assessment; eczema area and severity index; pruritis numeric rating scale;

D O I：

10.1093/bjd/ljae266.005

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

619

引用

页数：2

共 50 条

[31] Results from a phase IIa randomized, double-blind, placebo-controlled, exploratory, multicentre study of GBR 830 in adults with moderate-to-severe atopic dermatitis
Guttman-Yassky, E.
Pavel, A.
Estrada, Y.
Zhang, N.
Peng, X.
Xu, H.
Wen, H.
Fang, H.
Salhi, Y.
Gudi, G.
Ca, V.
Gn, S.
Grossman, F.
Wolff, G.
BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (01) : E44 - E45
[32] Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized Phase 3 clinical trials
Hebert, Adelaide
Flohr, Carsten
Hong, H. Chih-ho
Irvine, Alan
Pierce, Evangeline
Elmaraghy, Hany
Xu, Wen
Pillai, Sreekumar
Dawson, Zach
Siegfried, Elaine
Weidinger, Stephan
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB159 - AB159
[33] Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
Hebert, Adelaide A.
Flohr, Carsten
Hong, H. Chih-ho
Irvine, Alan D.
Pierce, Evangeline
Elmaraghy, Hany
Pillai, Sreekumar
Dawson, Zach
Chen, Sherry
Armengol, Clara
Siegfried, Elaine
Weidinger, Stephan
JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
[34] Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
Hebert, Adelaide
Flohr, Carsten
Hong, H. Chih-ho
Irvine, Alan
Pierce, Evangeline
Elmaraghy, Hany
Xu, Wen
Pillai, Sreekumar
Dawson, Zach
Siegfried, Elaine
Weidinger, Stephan
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[35] Interleukin-33 antibody failed to demonstrate benefit in a phase II, double-blind, randomized, placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis
Laquer, Vivian
Parra, Viviana
Lacour, Jean-Philippe
Takahashi, Hidetoshi
Knorr, Jack
Okragly, Angela J.
James, Douglas E.
Sims, Jonathan T.
Chang, Ching-Yun
Chao, Jeannie
Klekotka, Paul
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (04) : 599 - 602
[36] Cyclosporine for moderate-to-severe alopecia areata: A double-blind, randomized, placebo-controlled clinical trial of efficacy and safety
Lai, Vivien Wai Yun
Chen, Gang
Gin, Douglas
Sinclair, Rodney
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (03) : 694 - 701
[37] Vidofludimus Calcium in Patients With Moderate-to-Severe Ulcerative Colitis: A Randomized, Placebo-Controlled, Phase 2 Trial
D'Haens, Geert
Stardelova, Kalina Grivcheva
Sadiku, Edite
Kizlova, Natallia
Skybalo, Syitlana
Shehovtsova, Yulia
Abramescu, Mirela
Vitt, Daniel
Kohlhof, Hella
Muehler, Andreas
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2025, 16 (03)
[38] Efficacy and Safety of Upadacitinib in Moderate-to-Severe Hidradenitis Suppurativa: A Phase 2, Randomized, Placebo-Controlled Study
Kimball, Alexa B.
Ackerman, Lindsay
Schlosser, Bethanee J.
Prajapati, Vimal H.
Fretzin, Scott
Takahashi, Hidetoshi
Zhan, Tianyu
Huang, Xiaohong
Camp, Heidi S.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB42 - AB42
[39] Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: 52-Week Results of Two Randomized, Double-Blinded, Placebo-Controlled Phase 3 Trials (ADvocate1 and ADvocate2)
Marquardt, Tzvetelina
Blauvelt, Andrew
Thyssen, Jacob P.
Guttman-Yassky, Emma
Bieber, Thomas
Serra-Baldrich, Esther
Simpson, Eric
Rosmarin, David
Elmaraghy, Hany
Meskimen, Eric
Natalie, Chitra R.
Liu, Zhuqing
Xu, Chenjia
Pierce, Evangeline
Morgan-Cox, MaryAnn
Silverberg, Jonathan
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 61 - 62
[40] Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials
Simpson, Eric L.
Merola, Joseph F.
Silverberg, Jonathan, I
Reich, Kristian
Warren, Richard B.
Staumont-Salle, Delphine
Girolomoni, Giampiero
Papp, Kim
de Bruin-Weller, Marjolein
Thyssen, Jacob P.
Zachariae, Rebecca
Olsen, Christiana K.
Wollenberg, Andreas
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (06) : 888 - 899

← 1 2 3 4 5 →